Premium
Double‐blind study of an α 2 agonist in the treatment of irritable bowel syndrome
Author(s) -
PRIOR A.,
WILSON K. M.,
WHORWELL P. J.
Publication year - 1988
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1988.tb00728.x
Subject(s) - irritable bowel syndrome , medicine , bloating , agonist , abdominal pain , gastroenterology , double blind , crossover study , pathology , alternative medicine , placebo , receptor
SUMMARY A double‐blind crossover trial of the α 2 agonist lidamidine hydrochloride in 72 patients with irritable bowel syndrome is reported. Lidamidine was found to have no significant effect on frequency and severity of abdominal pain or abdominal bloating. It did cause a statistically significant reduction in frequency of defaecation ( P = 0.005), but this was of a degree unlikely to be of clinical importance. Although α 2 agonists inhibit gastrointestinal motility in animals this study suggests that lidamidine hydrochloride does not have a useful therapeutic role in irritable bowel syndrome.